Martin DE - Search Results

1

Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction.

Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE. Tran JQ, et al. Among authors: martin de. J Clin Pharmacol. 1999 May;39(5):487-94. J Clin Pharmacol. 1999. PMID: 10234596

2

Urine drug screening results from volunteers in phase I clinical pharmacology studies: are we being misled?

Ramey KL, Kovacs SJ, Martin DE, Jorkasky DK. Ramey KL, et al. Among authors: martin de. J Clin Pharmacol. 1998 May;38(5):413-6. doi: 10.1002/j.1552-4604.1998.tb04445.x. J Clin Pharmacol. 1998. PMID: 9602952

3

Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations.

Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK. Kovacs SJ, et al. Among authors: martin de. Clin Pharmacol Ther. 1998 Jun;63(6):617-22. doi: 10.1016/S0009-9236(98)90084-4. Clin Pharmacol Ther. 1998. PMID: 9663175 Clinical Trial.

4

Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.

Kovacs SJ, Tenero DM, Martin DE, Ilson BE, Jorkasky DK. Kovacs SJ, et al. Among authors: martin de. Pharmacotherapy. 1999 May;19(5):612-9. doi: 10.1592/phco.19.8.612.31518. Pharmacotherapy. 1999. PMID: 10331824 Clinical Trial.

5

The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension.

Ilson BE, Martin DE, Boike SC, Jorkasky DK. Ilson BE, et al. Among authors: martin de. J Clin Pharmacol. 1998 May;38(5):437-41. doi: 10.1002/j.1552-4604.1998.tb04450.x. J Clin Pharmacol. 1998. PMID: 9602957 Clinical Trial.

6

Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.

Martin DE, Chapelsky MC, Ilson B, Tenero D, Boike SC, Zariffa N, Jorkasky DK. Martin DE, et al. J Clin Pharmacol. 1998 Feb;38(2):129-37. doi: 10.1002/j.1552-4604.1998.tb04401.x. J Clin Pharmacol. 1998. PMID: 9549643

7

Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.

Martin DE, DeCherney GS, Ilson BE, Jones BA, Boike SC, Freed MI, Jorkasky DK. Martin DE, et al. J Clin Pharmacol. 1997 Feb;37(2):155-9. doi: 10.1002/j.1552-4604.1997.tb04774.x. J Clin Pharmacol. 1997. PMID: 9055142 Clinical Trial.

8

Eprosartan does not affect the pharmacodynamics of warfarin.

Kazierad DJ, Martin DE, Ilson B, Boike S, Zariffa N, Forrest A, Jorkasky DK. Kazierad DJ, et al. Among authors: martin de. J Clin Pharmacol. 1998 Jul;38(7):649-53. doi: 10.1002/j.1552-4604.1998.tb04473.x. J Clin Pharmacol. 1998. PMID: 9702851 Clinical Trial.

9

Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.

Martin DE, Tompson D, Boike SC, Tenero D, Ilson B, Citerone D, Jorkasky DK. Martin DE, et al. Br J Clin Pharmacol. 1997 Jun;43(6):661-4. doi: 10.1046/j.1365-2125.1997.00608.x. Br J Clin Pharmacol. 1997. PMID: 9205830 Free PMC article. Clinical Trial.

10

A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.

Ilson BE, Boike SC, Martin DE, Freed MI, Zariffa N, Jorkasky DK. Ilson BE, et al. Among authors: martin de. Clin Pharmacol Ther. 1998 Apr;63(4):471-81. doi: 10.1016/S0009-9236(98)90043-1. Clin Pharmacol Ther. 1998. PMID: 9585802 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters